Detalhe da pesquisa
1.
Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents.
Br J Haematol
; 204(3): 898-909, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37946611
2.
Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study.
Leuk Res
; 94: 106369, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32442785